Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Placental release of taurine to both the maternal and fetal circulations in human term pregnancies.

Holm MB, Kristiansen O, Holme AM, Bastani NE, Horne H, Blomhoff R, Haugen G, Henriksen T, Michelsen TM.

Amino Acids. 2018 Jun 1. doi: 10.1007/s00726-018-2576-9. [Epub ahead of print]

PMID:
29858686
2.

E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium.

Horne HN, Oh H, Sherman ME, Palakal M, Hewitt SM, Schmidt MK, Milne RL, Hardisson D, Benitez J, Blomqvist C, Bolla MK, Brenner H, Chang-Claude J, Cora R, Couch FJ, Cuk K, Devilee P, Easton DF, Eccles DM, Eilber U, Hartikainen JM, Heikkilä P, Holleczek B, Hooning MJ, Jones M, Keeman R, Mannermaa A, Martens JWM, Muranen TA, Nevanlinna H, Olson JE, Orr N, Perez JIA, Pharoah PDP, Ruddy KJ, Saum KU, Schoemaker MJ, Seynaeve C, Sironen R, Smit VTHBM, Swerdlow AJ, Tengström M, Thomas AS, Timmermans AM, Tollenaar RAEM, Troester MA, van Asperen CJ, van Deurzen CHM, Van Leeuwen FF, Van't Veer LJ, García-Closas M, Figueroa JD.

Sci Rep. 2018 Apr 26;8(1):6574. doi: 10.1038/s41598-018-23733-4.

3.

FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.

Ison G, Howie LJ, Amiri-Kordestani L, Zhang L, Tang S, Sridhara R, Pierre V, Charlab R, Ramamoorthy A, Song P, Li F, Yu J, Manheng W, Palmby TR, Ghosh S, Horne HN, Lee EY, Philip R, Dave K, Chen XH, Kelly SL, Janoria KG, Banerjee A, Eradiri O, Dinin J, Goldberg KB, Pierce WF, Ibrahim A, Kluetz PG, Blumenthal GM, Beaver JA, Pazdur R.

Clin Cancer Res. 2018 Apr 12. doi: 10.1158/1078-0432.CCR-18-0042. [Epub ahead of print]

PMID:
29650751
4.

Serum insulin-like growth factor (IGF)-I and IGF binding protein-3 in relation to terminal duct lobular unit involution of the normal breast in Caucasian and African American women: The Susan G. Komen Tissue Bank.

Oh H, Pfeiffer RM, Falk RT, Horne HN, Xiang J, Pollak M, Brinton LA, Storniolo AMV, Sherman ME, Gierach GL, Figueroa JD.

Int J Cancer. 2018 Aug 1;143(3):496-507. doi: 10.1002/ijc.31333. Epub 2018 Apr 1.

PMID:
29473153
5.

The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo.

Holme AM, Holm MB, Roland MCP, Horne H, Michelsen TM, Haugen G, Henriksen T.

J Vis Exp. 2017 Aug 2;(126). doi: 10.3791/55847.

PMID:
28809844
6.

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer.

Balasubramaniam S, Beaver JA, Horton S, Fernandes LL, Tang S, Horne HN, Liu J, Liu C, Schrieber SJ, Yu J, Song P, Pierce W, Robertson KJ, Palmby TR, Chiu HJ, Lee EY, Philip R, Schuck R, Charlab R, Banerjee A, Chen XH, Wang X, Goldberg KB, Sridhara R, Kim G, Pazdur R.

Clin Cancer Res. 2017 Dec 1;23(23):7165-7170. doi: 10.1158/1078-0432.CCR-17-1337. Epub 2017 Jul 27.

PMID:
28751443
7.

Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia.

Liebman HA, Saleh MN, Bussel JB, Negrea OG, Horne H, Wegener WA, Goldenberg DM.

Haematologica. 2016 Nov;101(11):1327-1332. Epub 2016 Aug 11.

8.

Relation of Serum Estrogen Metabolites with Terminal Duct Lobular Unit Involution Among Women Undergoing Diagnostic Image-Guided Breast Biopsy.

Oh H, Khodr ZG, Sherman ME, Palakal M, Pfeiffer RM, Linville L, Geller BM, Vacek PM, Weaver DL, Chicoine RE, Falk RT, Horne HN, Papathomas D, Patel DA, Xiang J, Xu X, Veenstra T, Hewitt SM, Shepherd JA, Brinton LA, Figueroa JD, Gierach GL.

Horm Cancer. 2016 Dec;7(5-6):305-315. Epub 2016 May 2.

9.

Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus.

Horne HN, Chung CC, Zhang H, Yu K, Prokunina-Olsson L, Michailidou K, Bolla MK, Wang Q, Dennis J, Hopper JL, Southey MC, Schmidt MK, Broeks A, Muir K, Lophatananon A, Fasching PA, Beckmann MW, Fletcher O, Johnson N, Sawyer EJ, Tomlinson I, Burwinkel B, Marme F, Guénel P, Truong T, Bojesen SE, Flyger H, Benitez J, González-Neira A, Anton-Culver H, Neuhausen SL, Brenner H, Arndt V, Meindl A, Schmutzler RK, Brauch H, Hamann U, Nevanlinna H, Khan S, Matsuo K, Iwata H, Dörk T, Bogdanova NV, Lindblom A, Margolin S, Mannermaa A, Kosma VM, Chenevix-Trench G; kConFab/AOCS Investigators, Wu AH, Ven den Berg D, Smeets A, Zhao H, Chang-Claude J, Rudolph A, Radice P, Barile M, Couch FJ, Vachon C, Giles GG, Milne RL, Haiman CA, Marchand LL, Goldberg MS, Teo SH, Taib NA, Kristensen V, Borresen-Dale AL, Zheng W, Shrubsole M, Winqvist R, Jukkola-Vuorinen A, Andrulis IL, Knight JA, Devilee P, Seynaeve C, García-Closas M, Czene K, Darabi H, Hollestelle A, Martens JW, Li J, Lu W, Shu XO, Cox A, Cross SS, Blot W, Cai Q, Shah M, Luccarini C, Baynes C, Harrington P, Kang D, Choi JY, Hartman M, Chia KS, Kabisch M, Torres D, Jakubowska A, Lubinski J, Sangrajrang S, Brennan P, Slager S, Yannoukakos D, Shen CY, Hou MF, Swerdlow A, Orr N, Simard J, Hall P, Pharoah PD, Easton DF, Chanock SJ, Dunning AM, Figueroa JD.

PLoS One. 2016 Aug 24;11(8):e0160316. doi: 10.1371/journal.pone.0160316. eCollection 2016.

10.

Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast disease.

Horne HN, Sherman ME, Pfeiffer RM, Figueroa JD, Khodr ZG, Falk RT, Pollak M, Patel DA, Palakal MM, Linville L, Papathomas D, Geller B, Vacek PM, Weaver DL, Chicoine R, Shepherd J, Mahmoudzadeh AP, Wang J, Fan B, Malkov S, Herschorn S, Hewitt SM, Brinton LA, Gierach GL.

Breast Cancer Res. 2016 Feb 18;18(1):24. doi: 10.1186/s13058-016-0678-4.

11.

Relationship of Terminal Duct Lobular Unit Involution of the Breast with Area and Volume Mammographic Densities.

Gierach GL, Patel DA, Pfeiffer RM, Figueroa JD, Linville L, Papathomas D, Johnson JM, Chicoine RE, Herschorn SD, Shepherd JA, Wang J, Malkov S, Vacek PM, Weaver DL, Fan B, Mahmoudzadeh AP, Palakal M, Xiang J, Oh H, Horne HN, Sprague BL, Hewitt SM, Brinton LA, Sherman ME.

Cancer Prev Res (Phila). 2016 Feb;9(2):149-58. doi: 10.1158/1940-6207.CAPR-15-0282. Epub 2015 Dec 8.

12.

Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia.

Kalaycio ME, George Negrea O, Allen SL, Rai KR, Abbasi RM, Horne H, Wegener WA, Goldenberg DM.

Leuk Lymphoma. 2016;57(4):803-11. doi: 10.3109/10428194.2015.1085531. Epub 2015 Oct 19.

PMID:
26389849
13.

(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.

Picozzi VJ, Ramanathan RK, Lowery MA, Ocean AJ, Mitchel EP, O'Neil BH, Guarino MJ, Conkling PR, Cohen SJ, Bahary N, Frank RC, Dragovich T, Bridges BB, Braiteh FS, Starodub AN, Lee FC, Gribbin TE, Richards DA, Lee M, Korn RL, Pandit-Taskar N, Goldsmith SJ, Intenzo CM, Sheikh A, Manzone TC, Horne H, Sharkey RM, Wegener WA, O'Reilly EM, Goldenberg DM, Von Hoff DD.

Eur J Cancer. 2015 Sep;51(14):1857-64. doi: 10.1016/j.ejca.2015.06.119. Epub 2015 Jul 14.

14.

Integrated analysis of DNA methylation, immunohistochemistry and mRNA expression, data identifies a methylation expression index (MEI) robustly associated with survival of ER-positive breast cancer patients.

Figueroa JD, Yang H, Garcia-Closas M, Davis S, Meltzer P, Lissowska J, Horne HN, Sherman ME, Lee M.

Breast Cancer Res Treat. 2015 Apr;150(2):457-466. doi: 10.1007/s10549-015-3314-6. Epub 2015 Mar 15.

15.

Greater absolute risk for all subtypes of breast cancer in the US than Malaysia.

Horne HN, Beena Devi CR, Sung H, Tang TS, Rosenberg PS, Hewitt SM, Sherman ME, Anderson WF, Yang XR.

Breast Cancer Res Treat. 2015 Jan;149(1):285-91. doi: 10.1007/s10549-014-3243-9. Epub 2014 Dec 24.

PMID:
25537643
16.

Effect of patient navigation on colorectal cancer screening in a community-based randomized controlled trial of urban African American adults.

Horne HN, Phelan-Emrick DF, Pollack CE, Markakis D, Wenzel J, Ahmed S, Garza MA, Shapiro GR, Bone LR, Johnson LB, Ford JG.

Cancer Causes Control. 2015 Feb;26(2):239-246. doi: 10.1007/s10552-014-0505-0. Epub 2014 Dec 17.

17.

A robust association test for detecting genetic variants with heterogeneous effects.

Yu K, Zhang H, Wheeler W, Horne HN, Chen J, Figueroa JD.

Biostatistics. 2015 Jan;16(1):5-16. doi: 10.1093/biostatistics/kxu036. Epub 2014 Jul 23.

18.

On the formation of a protic ionic liquid in nature.

Chen L, Mullen GE, Le Roch M, Cassity CG, Gouault N, Fadamiro HY, Barletta RE, O'Brien RA, Sykora RE, Stenson AC, West KN, Horne HE, Hendrich JM, Xiang KR, Davis JH Jr.

Angew Chem Int Ed Engl. 2014 Oct 27;53(44):11762-5. doi: 10.1002/anie.201404402. Epub 2014 Jul 17.

PMID:
25045040
19.

Allergy to oxidized limonene and linalool is frequent in the U.K.

Audrain H, Kenward C, Lovell CR, Green C, Ormerod AD, Sansom J, Chowdhury MM, Cooper SM, Johnston GA, Wilkinson M, King C, Stone N, Horne HL, Holden CR, Wakelin S, Buckley DA.

Br J Dermatol. 2014 Aug;171(2):292-7. doi: 10.1111/bjd.13037. Epub 2014 Jul 26.

PMID:
24702129
20.

Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expression.

Horne HN, Sherman ME, Garcia-Closas M, Pharoah PD, Blows FM, Yang XR, Hewitt SM, Conway CM, Lissowska J, Brinton LA, Prokunina-Olsson L, Dawson SJ, Caldas C, Easton DF, Chanock SJ, Figueroa JD.

Breast Cancer Res Treat. 2014 Jan;143(1):181-7. doi: 10.1007/s10549-013-2771-z. Epub 2013 Nov 30.

21.

First trimester maternal serum alpha-fetoprotein is not raised in pregnancies with open spina bifida.

Spencer K, Khalil A, Brown L, Mills I, Horne H.

Prenat Diagn. 2014 Feb;34(2):168-71. doi: 10.1002/pd.4280. Epub 2013 Dec 9.

PMID:
24226839
22.

Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.

Kaufman JL, Niesvizky R, Stadtmauer EA, Chanan-Khan A, Siegel D, Horne H, Wegener WA, Goldenberg DM.

Br J Haematol. 2013 Nov;163(4):478-86. doi: 10.1111/bjh.12565. Epub 2013 Sep 25.

PMID:
24112026
23.

Health disparities around the world: perspectives from the 2012 Principles and Practice of Cancer Prevention and Control course at the National Cancer Institute.

Chawla N, Kepka DL, Heckman-Stoddard BM, Horne HN, Felix AS, Luhn P, Pelser C, Barkley J, Faupel-Badger JM.

J Oncol Pract. 2013 Nov;9(6):e284-9. doi: 10.1200/JOP.2013.001129. Epub 2013 Oct 1.

24.

Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study.

Liebman HA, Saleh MN, Bussel JB, Negrea OG, Horne H, Wegener WA, Goldenberg DM.

Br J Haematol. 2013 Sep;162(5):693-701. doi: 10.1111/bjh.12448. Epub 2013 Jul 6.

PMID:
23829485
25.

Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.

Ocean AJ, Pennington KL, Guarino MJ, Sheikh A, Bekaii-Saab T, Serafini AN, Lee D, Sung MW, Gulec SA, Goldsmith SJ, Manzone T, Holt M, O'Neil BH, Hall N, Montero AJ, Kauh J, Gold DV, Horne H, Wegener WA, Goldenberg DM.

Cancer. 2012 Nov 15;118(22):5497-506. doi: 10.1002/cncr.27592. Epub 2012 May 8.

26.

Current patch test results with the European baseline series and extensions to it from the 'European Surveillance System on Contact Allergy' network, 2007-2008.

Uter W, Aberer W, Armario-Hita JC, Fernandez-Vozmediano JM, Ayala F, Balato A, Bauer A, Ballmer-Weber B, Beliauskiene A, Fortina AB, Bircher A, Brasch J, Chowdhury MM, Coenraads PJ, Schuttelaar ML, Cooper S, Czarnecka-Operacz M, Zmudzinska M, Elsner P, English JS, Frosch PJ, Fuchs T, García-Gavín J, Fernández-Redondo V, Gawkrodger DJ, Giménez-Arnau A, Green CM, Horne HL, Johansen JD, Jolanki R, Pesonen M, King CM, Krêcisz B, Chomiczewska D, Kiec-Swierczynska M, Larese F, Mahler V, Ormerod AD, Peserico A, Rantanen T, Rustemeyer T, Sánchez-Pérez J, Sansom JE, Silvestre JF, Simon D, Spiewak R, Statham BN, Stone N, Wilkinson M, Schnuch A.

Contact Dermatitis. 2012 Jul;67(1):9-19. doi: 10.1111/j.1600-0536.2012.02070.x. Epub 2012 Apr 15.

PMID:
22500724
27.

Skin fragility and blistering secondary to imatinib.

Reddy H, Horne HL, Maung Z.

Clin Exp Dermatol. 2012 Jul;37(5):572-3. doi: 10.1111/j.1365-2230.2011.04289.x. Epub 2012 Jan 9. No abstract available.

PMID:
22224491
28.

Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial.

Gulec SA, Cohen SJ, Pennington KL, Zuckier LS, Hauke RJ, Horne H, Wegener WA, Teoh N, Gold DV, Sharkey RM, Goldenberg DM.

Clin Cancer Res. 2011 Jun 15;17(12):4091-100. doi: 10.1158/1078-0432.CCR-10-2579. Epub 2011 Apr 28.

29.

Prevalence and risk factors for anal incontinence after obstetric anal sphincter rupture.

Laine K, Skjeldestad FE, Sanda B, Horne H, Spydslaug A, Staff AC.

Acta Obstet Gynecol Scand. 2011 Apr;90(4):319-24. doi: 10.1111/j.1600-0412.2010.01057.x. Epub 2011 Feb 15.

PMID:
21306321
30.

Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma.

Negrea GO, Elstrom R, Allen SL, Rai KR, Abbasi RM, Farber CM, Teoh N, Horne H, Wegener WA, Goldenberg DM.

Haematologica. 2011 Apr;96(4):567-73. doi: 10.3324/haematol.2010.037390. Epub 2010 Dec 20.

31.

High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.

Morschhauser F, Kraeber-Bodéré F, Wegener WA, Harousseau JL, Petillon MO, Huglo D, Trümper LH, Meller J, Pfreundschuh M, Kirsch CM, Naumann R, Kropp J, Horne H, Teoh N, Le Gouill S, Bodet-Milin C, Chatal JF, Goldenberg DM.

J Clin Oncol. 2010 Aug 10;28(23):3709-16. doi: 10.1200/JCO.2009.27.7863. Epub 2010 Jul 12.

PMID:
20625137
32.

The importance of propolis in patch testing--a multicentre survey.

Rajpara S, Wilkinson MS, King CM, Gawkrodger DJ, English JS, Statham BN, Green C, Sansom JE, Chowdhury MM, Horne HL, Ormerod AD.

Contact Dermatitis. 2009 Nov;61(5):287-90. doi: 10.1111/j.1600-0536.2009.01629.x.

PMID:
19878244
33.

A review of the materials and allergens in protective gloves.

Rose RF, Lyons P, Horne H, Mark Wilkinson S.

Contact Dermatitis. 2009 Sep;61(3):129-37. doi: 10.1111/j.1600-0536.2009.01580.x. Review.

PMID:
19780770
34.

The European baseline series in 10 European Countries, 2005/2006--results of the European Surveillance System on Contact Allergies (ESSCA).

Uter W, Rämsch C, Aberer W, Ayala F, Balato A, Beliauskiene A, Fortina AB, Bircher A, Brasch J, Chowdhury MM, Coenraads PJ, Schuttelaar ML, Cooper S, Corradin MT, Elsner P, English JS, Fartasch M, Mahler V, Frosch PJ, Fuchs T, Gawkrodger DJ, Gimènez-Arnau AM, Green CM, Horne HL, Jolanki R, King CM, Krêcisz B, Kiec-Swierczynska M, Ormerod AD, Orton DI, Peserico A, Rantanen T, Rustemeyer T, Sansom JE, Simon D, Statham BN, Wilkinson M, Schnuch A.

Contact Dermatitis. 2009 Jul;61(1):31-8. doi: 10.1111/j.1600-0536.2009.01572.x.

PMID:
19659962
35.

Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.

Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N, Wegener WA, Goldenberg DM.

J Clin Oncol. 2009 Jul 10;27(20):3346-53. doi: 10.1200/JCO.2008.19.9117. Epub 2009 May 18.

PMID:
19451441
36.

Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome.

Berchuck A, Iversen ES, Luo J, Clarke JP, Horne H, Levine DA, Boyd J, Alonso MA, Secord AA, Bernardini MQ, Barnett JC, Boren T, Murphy SK, Dressman HK, Marks JR, Lancaster JM.

Clin Cancer Res. 2009 Apr 1;15(7):2448-55. doi: 10.1158/1078-0432.CCR-08-2430. Epub 2009 Mar 24.

37.

Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy.

Horne HN, Lee PS, Murphy SK, Alonso MA, Olson JA Jr, Marks JR.

Mol Cancer Res. 2009 Feb;7(2):199-209. doi: 10.1158/1541-7786.MCR-08-0314. Epub 2009 Feb 10.

38.

Cervical length screening in patients who have undergone loop electrosurgical excision procedure.

Parikh R, Horne H, Feinstein SJ, Anasti JN.

J Reprod Med. 2008 Dec;53(12):909-13.

PMID:
19160648
39.

Leather suite dermatitis.

Darné S, Horne HL.

Br J Dermatol. 2008 Jul;159(1):262-4. doi: 10.1111/j.1365-2133.2008.08637.x. Epub 2008 Jul 1. No abstract available.

PMID:
18503596
40.

Differentiating psychotic patients from nonpsychotic patients with the MMPI-2 and Rorschach.

Dao TK, Prevatt F, Horne HL.

J Pers Assess. 2008 Jan;90(1):93-101. doi: 10.1080/00223890701693819.

PMID:
18444100
41.

Dicaprylyl maleate--an emerging cosmetic allergen.

Lotery H, Kirk S, Beck M, Burova E, Crone M, Curley R, Downs A, Hill G, Horne H, Iftikhar N, Lovell C, Malanin K, Orton D, Powell S, Sansom J, Sonnex T, Todd D, Tucker S, Wilkinson M, Haworth A.

Contact Dermatitis. 2007 Sep;57(3):169-72.

PMID:
17680866
42.

Tixocortol pivalate: what is the right concentration?

Kalavala M, Statham BN, Green CM, King C, Ormerod AD, Sansom J, English JS, Wilkinson MS, Horne H, Gawkrodger D.

Contact Dermatitis. 2007 Jul;57(1):44-6.

PMID:
17577357
43.

A multicentre review of the footwear allergens tested in the UK.

Katugampola RP, Statham BN, English JS, Wilkinson MM, Foulds IS, Green CM, Ormerod AD, Stone NM, Horne HL, Chowdhury MM.

Contact Dermatitis. 2005 Sep;53(3):133-5.

PMID:
16128751
44.

A multicentre review of the hairdressing allergens tested in the UK.

Katugampola RP, Statham BN, English JS, Wilkinson MM, Foulds IS, Green CM, Ormerod AD, Stone NM, Horne HL, Chowdhury MM.

Contact Dermatitis. 2005 Sep;53(3):130-2.

PMID:
16128750
45.

Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.

Lindén O, Hindorf C, Cavallin-Ståhl E, Wegener WA, Goldenberg DM, Horne H, Ohlsson T, Stenberg L, Strand SE, Tennvall J.

Clin Cancer Res. 2005 Jul 15;11(14):5215-22.

46.

Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.

Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman RR, Niesvizky R, Shore T, Chadburn A, Horne H, Kovacs J, Ding CL, Wegener WA, Horak ID, Goldenberg DM.

J Clin Oncol. 2005 Aug 1;23(22):5044-51. Epub 2005 Jun 13.

PMID:
15955901
47.

Transitions in replication timing in a 340 kb region of human chromosomal R-Band 1p36.1.

Brylawski BP, Cohen SM, Horne H, Irani N, Cordeiro-Stone M, Kaufman DG.

J Cell Biochem. 2004 Jul 1;92(4):755-69.

PMID:
15211573
49.

Juvenile nodulocystic acne responding to systemic isotretinoin.

Horne HL, Carmichael AJ.

Br J Dermatol. 1997 May;136(5):796-7. Review. No abstract available.

PMID:
9205525
50.

Validity studies of the filial anxiety scale.

Murray PD, Lowe JD Jr, Anderson HN, Horne HL, Lott WC, MacDonald S.

Gerontologist. 1996 Feb;36(1):110-2.

PMID:
8932417

Supplemental Content

Support Center